enhancement – genetic and cosmetic pharmacology orla sheils

57
Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Upload: madlyn-banks

Post on 26-Dec-2015

225 views

Category:

Documents


5 download

TRANSCRIPT

Page 1: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Enhancement – Genetic and Cosmetic Pharmacology

Orla Sheils

Page 2: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Enhancement

• Breakthroughs in genetics present us with a promise and a predicament.

• The promise is that we will soon be able to treat and prevent a host of debilitating diseases.

• The predicament is that our newfound genetic knowledge may enable us to manipulate our nature – – to enhance our genetic traits and those of our children.

• Although most people find at least some forms of genetic engineering disquieting, it is not easy to articulate, why?

Page 3: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Enhancement

• What is wrong with re-engineering our nature? “• In this session we will explore these and other

moral quandaries connected with the quest to perfect ourselves and our children.

• Some argue that the pursuit of perfection is flawed for reasons that go beyond safety and fairness.

• The drive to enhance human nature through genetic technologies is objectionable because it represents a bid for mastery and dominion that fails to appreciate the gifted character of human powers and achievements.

Page 4: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Enhancement

• Perhaps the genetic revolution will change the way philosophers discuss ethics and will force spiritual questions back onto the political agenda.

• In order to grapple with the ethics of enhancement, we need to confront questions largely lost from view in the modern world.

• Since these questions verge on theology, modern philosophers and political theorists tend to shrink from them.

• But our new powers of biotechnology make these questions unavoidable. ..

Page 5: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Enhancement

• controversial issue regarding biotechnology is the prospect of employing it for the purpose of human enhancement .

• demarcation problem: – What is enhancement and what is it being

contrasted with?– primary modification people have in mind is

genetic, but it is worth looking at non-genetic modifications

Page 6: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Demarcation

• therapeutic modification is one that brings a trait that was below a recognizable, species-wide norm up to that norm.

• an enhancement modification in contrast as one that is a non-therapeutic improvement. – The norm referred to here is the one that

separates conditions of health from those of disease

Page 7: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

BUT

• the health/disease distinction is of limited use in explaining the enhancement/therapy distinction

Page 8: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Value judgments

• what constitutes the norm?

• Is the judgment that someone is diseased ?

• Is a particular condition a disease independent of whether we think it is bad or undesirable?

• Can a condition be a disease in one culture and not in another?

Page 9: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

• If what constitutes enhancement varies with individual or culture – -if enhancement is in the eye of the

beholder –

• then it is not clear that we can sensibly articulate an (ethical) issue about enhancement as such.

Page 10: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Enhancement/therapy distinction

• One class of cases are modifications that, strictly speaking are enhancements, but whose purpose is to respond to (the threat of) a disease.

• For example, a modification that improves people's resistance to particular diseases beyond the normal capacity would count as an enhancement but its purpose would be disease prevention and so arguably therapeutic.– Cf vaccination

Page 11: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

• ambiguity in the idea of "normal traits."

• Moreover, normality itself often refers to a range within a trait rather than to a sharp line. – Short stature

Page 12: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Biotechnology covers a range of technologies and procedures, many of which could conceivably be employed for enhancement.

But the most discussed enhancement technology is one in which a person's genome is altered.

Page 13: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

• Genetic modifications are often separated into two kinds - somatic and germline. – difference is whether the particular genetic

modification affects the individual's gametes so that the modification can be passed on to the individual's offspring.

– The object of a somatic modification is a modified individual,

– but the object of a germline modification is a modification that becomes part of the individual's legacy or inheritance.

Page 14: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Designer Children

• Used pejoratively to describe children of parents more concerned with fashion than valuing children for their own sake.

• Is choosing a same race child designing the child you will have?

• It is a truism that bears repeating that once a person has capacity to choose and awareness of that capacity- then choice is inevitable.

Page 15: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

• The Nuffield Council report on genetic screening distinguishes between legitimate and illegitimate uses of genetic screening.

• It makes the boundary between legitimate choices and unacceptable eugenics choices at the point where:– “the decisions are subjugated to those aims

considered to be of benefit to the population or the state”.

Page 16: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

How it still happens

Page 17: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Truth

• One in six couples have problems conceiving.

Page 18: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Male infertility

• Male has poor sperm

• Intrauterine insemination (AIH)

• Assisted Reproduction

Page 19: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Male infertility

• Male has no sperm

• Artificial insemination by donor (AID)

• Assisted Reproduction

Page 20: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Female infertility

• Anovulation (PCO/ HH)– Ovulation induction

• Assisted Reproduction

Page 21: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Female infertility

• Tubal factor/ Endometriosis

• Assisted Reproduction

Page 22: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Female infertility

• Ovarian failure

• Assisted Reproduction with donor eggs

Page 23: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

The solution or the problem?

Page 24: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Let’s copy nature

+

egg (oocyte) sperm

Page 25: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

The first

25th July 1978

Louise Brown, Oldham General Hospital

Page 26: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

The media

Page 27: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

The team

Page 28: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Favoured by chance

Page 29: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

The downs?

• Emotional, physical drain

• Poor success rates, still.

• Not state funded

• Passing on the “problem”?

• What about ethical issues?

Page 30: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Endless list…

• Informed consent• Confidentiality• Research involving

genetic material• Screening (PGD,

antenatal)• Sex selection• Saviour siblings• Selecting for disability• Surrogacy

• Sperm, egg donation• Sale of gametes• Postmenopausal

motherhood• Rationing access to

reproductive services• Human reproductive

cloning• Fetal material in research

and treatment• Genetic enhancement

and therapy

Page 31: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Informed consent

• Relevant information• Opportunity for deliberation• Capacity (competence) to understand

information• Voluntary

– Relevant cases• Natalie Evans –UK• MR v TR

– concerning a separated couple that disagree about whether frozen embryos (fertilised and stored when the couple was still together) can be used to impregnate the woman over the objections of the man.

Page 32: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Research on genetic material

• Consent

• Adequate information/ counselling

• Impact

• Relevance

Page 33: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Screening

• Preimplantation

– Most acceptable– Risks not known

– Does the embryo have moral status?

• Antenatal

– Visible embryo– Involves

destruction of life already established

– Justified?– Does the fetus

have moral status?

Page 34: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Screening

• Moral status came into focus during the abortion debate.

Page 35: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

What is it to have moral status?

• It means that harm matters to the given thing (the moral status of which we are assessing).

Page 36: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

The fetus

• Part of the human species

• Sentient (feels pain)

• Qualifies for personhood (potential)

Page 37: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

PGD

Page 38: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Sex selection

• Preimplantation Genetic Diagnosis

• One blastomere

• PCR/ FISH

Page 39: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Sex selection

• Therapeutic

– Avoid inheritable disease

– Haemophilia– Duchenne

muscular dystrophy

• Non-therapeutic

– Family balancing– Preference– Replacement– Procreative

autonomy (how far?)

Page 40: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Saviour siblings • One created to cure/ save other

sibling.• Tissue match• Designer babies?

• Not creating child for itself.• This is a commodity rather than a

person.

Page 41: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Saviour Siblings

• Kantian prohibition on using people merely as a means to and end ?– might justifiably be argued if the new

sibling were created solely for the purposes of generating a donor for the existing child

Page 42: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Postmenopausal motherhood

• Welfare of the child

• Resource allocation

• Natural?

Page 43: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Surrogacy

• Arrangement (altruistic)

• Contract (commercial/ US)

• Surrogate – carry the pregnancy• Genetic • Gestational

Page 44: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Is it right?

• Allows couples to have a child which otherwise could not have been born.

• Women with very high risk for pregnancy can contemplate a genetic offspring.

• Women who enjoy pregnancy can do it for money.

• Altruistic

Page 45: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

• Traditional way of producing children is subject to prejudice or preference– not only for a certain type of partner but– subconsciously at the particular type of

child mating with that partner will produce.

Page 46: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Genetic Choices – Disability     • Serious practical possibility for people to

choose the type of children they will have: – Ante-natal testing followed by abortion – Selection using IVF -only implant embryos

with required genetic makeup

• Is the central issue one of procreative liberty?– Freedom to procreate is not something limited

to the individual– It is different to freedom of speech etc

Page 47: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

• In the UK and US ante-natal testing is run on the basis of personal choice.

• Nevertheless, the state has set up the programme. Is there a danger that the state/society has a subliminal influence on parents to produce the best child they can.

• Are there economic motives relating to cost benefit analysis and expense incurred by society if a disabled baby is born?

Page 48: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Selecting for disability

• Is it acceptable to deliberately choose to have a disabled child?

Page 49: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Deaf Lesbian Case

    • Lesbian couple decided to have a deaf baby.

– Many deaf people assert deafness is not a disability rather a social construct.

– Criticised for their choice –saying it was a pity to deprive a child of the full range of abilities open to it.

– If it is ok to select a child without disability is it ok to select for one with?

Page 50: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

• Not always a sharp boundary between knocking out a disability and enhancing a trait.– More clear-cut with single gene disorders, but

this applies to a small proportion of disease types.

• Not a sharp boundary between bottom of normal range and disease. – Often a subtle spectrum– e.g. Achondroplasia or clinical depression

Page 51: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Genetic Inequality

     • Unlikely Government will fund

enhancement • Market driven

– rich will purchase genotypes the poor can’t afford?

– We are used to inequality wrt wealth– In principle wealth can be redistributed

• Not so with genetic inequality

Page 52: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Positional Goods –Fred Hirsch

• Social limits to growth

• If everyone stands on tiptoe –nobody can see any better

• Were enhancement to become pervasive – there is no net benefit for an individual.

Page 53: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

Cosmetic Neuropharmacology

• Prozac

• Ritalin

• Memory enhancement

Page 54: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

• Arguments against use of prozac type drugs for non-clinically depressed patients.

• What is the societal impact?• But what is wrong with their use?

– Personal identity– Human nature– If you take 2 routes to get to a place does it

matter if you end at the correct place?

Page 55: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

• Worries that the kind of person Prozac makes you is the type valued in society.– Promotes masculine, assertive values

• Societal Medicalisation– Tendency to view social, personal and

political problems in biological or medical terms

Page 56: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

• Effect on personal identity– Elliot- we have a ‘true’ self– Previously achieved through spiritual

means– Currently society demands ‘quick fix’– Or we decide how we want to be and

assess methods of achieving that goal.

Page 57: Enhancement – Genetic and Cosmetic Pharmacology Orla Sheils

• ?temperament altering drugs for criminals?